Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Bringing together unparalleled healthcare data, advanced analytics, innovative technologies, and healthcare expertise to create intelligent connections that speed the development and commercialization of innovative medicines to improve patient lives.
Learn MoreAccelerate digital innovation to enable smarter decisions that reduce cost, modernize patient and consumer engagement, and improve health outcomes.
Learn MoreA curation of IQVIA's best thinking on topics and trends driving change, disruption, and progress in the United States healthcare market.
LEARN MOREExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTS
"Discover the future through our enlightening podcasts available in the United States.
EXPLORE PODCASTSAs companies realize the potential of Artificial Intelligence (AI) and Machine Learning (ML), applications in healthcare are expected to grow to nearly $8 billion by 2022. The biopharmaceutical industry is increasingly recognizing AI/ML’s potential to both improve decision making across R&D and commercialization, and to drive better outcomes for patients, physicians, and payers.
However, observers have yet to see meaningful and sustained realization of value from AI/ML in the biopharma industry. Further, most internal biopharma AI/ML initiatives remain fragmented and often separate from the main business.
In this white paper, IQVIA’s Data Science experts explore the reasons why AI/ML has had limited success in the biopharmaceutical industry to date, and contrast that examination with case studies spotlighting enterprises that successfully improved patient outcomes and streamlined internal operations through the use of AI/ML.
Download this white paper to discover how your biopharma organization can succeed in today’s increasingly complex and competitive environment by adopting AI/ML applications to enable:Decrease clinical development costs and increase study quality using our global functional resources and flexible services, and get more value from your R&D spend.
Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.
